Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz in pediatric vanishing white matter disease
2017-001438-25Phase 2Active
- Sponsor
- VU University Medical Center
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of guanabenz in leukoencephalopathy with vanishing white matter (VWM), sponsored by VU University Medical Center. Primary endpoint: Adverse events and serious adverse events. Started Nov 2018; status: active.
02
Drugs
guanabenz
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on 2017-001438-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001438-25.